A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
for Juvenile Psoriatic Arthritis
Drug: Deucravacitinib
7 locations incl. Lancaster
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 5 - 17
Code: NCT06869551·Phase 3·Recruiting